SCENESSE 16 mg implant

DRUG2 trials

Sponsors

Clinuvel Europe Limited, Clinuvel Inc.

Conditions

Erythropoietic Protoporphyria (EPP)Vitiligo

Phase 1

A Study to Evaluate the Pharmacokinetics of Afamelanotide in Patients with Erythropoietic Protoporphyria (EPP).

CompletedCTIS2023-507311-35-00

Clinuvel Europe LimitedErythropoietic Protoporphyria (EPP)

Start: 2024-03-07End: 2025-01-20Target: 26Updated: 2024-11-04

Phase 2

A Double-Arm, Open Label, Phase III Study to Compare the Efficacy and Safety of SCENESSE® and Narrow-Band Ultraviolet B (NB-UVB) Light versus NB-UVB Light Alone in the Treatment of Vitiligo

RecruitingCTIS2023-507470-40-00

Clinuvel Inc.Vitiligo

Start: 2024-08-27Target: 40Updated: 2026-01-21